With the bioeconomy and biopharma sectors contributing more than €3 trillion to the European economy in 2022/2023, biomanufacturing is increasingly recognised as a strategic pillar of the EU’s knowledge-driven economy. It plays a key role in building resilient and sustainable supply chains while supporting high-quality jobs across European regions.
Despite its importance, the EU remains the only major global region without a dedicated biomanufacturing initiative. Meanwhile, global competitors such as the United States, India and China are rapidly advancing in this field, with ambitious production and innovation targets across sectors including pharmaceuticals, food, industrial biotechnology, chemicals and materials.
While initiatives such as the EU Biotech Act are helping to accelerate innovation, a significant gap remains in scaling up from research to industrial production. Regulatory fragmentation and duplication across sectors and Member States continue to slow deployment and limit the full potential of the EU single market.
An ambitious EU Biomanufacturing Act is therefore needed to provide coordination, support market entry and scale-up, unlock private investment and strengthen industrial confidence. Such a framework would help ensure that Europe’s scientific excellence is translated into industrial leadership, resilient supply chains and long-term growth for the European bioeconomy.
A joint coalition of 40 signatory organisations, representing a wide range of industries that use and enable biomanufacturing processes and products, call for an ambitious EU Biomanufacturing Act which would contribute significantly to employment, innovation and economic growth in Europe.
